Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kane Biotech Inc KNBIF


Primary Symbol: V.KNE

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired... see more

Recent & Breaking News (TSXV:KNE)

Kane Biotech Receives ISO 13485:2016 MDSAP Quality Certification

GlobeNewswire July 17, 2024

Kane Biotech Announces Issuance of Restricted Share Units

GlobeNewswire July 15, 2024

Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.

GlobeNewswire July 11, 2024

Kane Biotech Makes First Commercial Sale of revyve(TM) Antimicrobial Wound Gel to ProgenaCare Global

GlobeNewswire June 27, 2024

Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.

GlobeNewswire June 25, 2024

Kane Biotech Announces First Quarter 2024 Financial Results

GlobeNewswire May 23, 2024

Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024

GlobeNewswire May 16, 2024

Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map

GlobeNewswire May 15, 2024

Kane Biotech to Host Investor Webinar

GlobeNewswire April 16, 2024

Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products

GlobeNewswire April 15, 2024

Kane Biotech to sell its STEM Animal Health for C$11.5 million

Jocelyn Aspa April 11, 2024

Canadian Investment Regulatory Organization Trade Resumption - KNE

Canada NewsWire April 11, 2024

Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health

GlobeNewswire April 11, 2024

Canadian Investment Regulatory Organization Trading Halt - KNE

Canada NewsWire April 11, 2024

Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire March 26, 2024

Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health

GlobeNewswire March 20, 2024

Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 - Conference Call to Follow

GlobeNewswire March 19, 2024

Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award

GlobeNewswire March 8, 2024

Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair

GlobeNewswire February 22, 2024

Kane Biotech Files New Patent on revyve(TM) Antimicrobial Wound Gel Spray

GlobeNewswire January 31, 2024